| 22.41 -2.57 (-10.29%) | 01-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.99 | 1-year : | 42.04 |
| Resists | First : | 30.81 | Second : | 35.99 |
| Pivot price | 18.55  |
|||
| Supports | First : | 16.73 |
Second : | 8.02 |
| MAs | MA(5) : | 21.71 |
MA(20) : | 16.55 |
| MA(100) : | 11.32 |
MA(250) : | 11.02 |
|
| MACD | MACD : | 3.4 |
Signal : | 2.9 |
| %K %D | K(14,3) : | 60.4 |
D(3) : | 56.4 |
| RSI | RSI(14): 65.4 |
|||
| 52-week | High : | 30.81 | Low : | 7.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GLSI ] has closed below upper band by 28.5%. Bollinger Bands are 410.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 24.96 - 25.08 | 25.08 - 25.18 |
| Low: | 20.73 - 20.87 | 20.87 - 20.99 |
| Close: | 22.2 - 22.43 | 22.43 - 22.61 |
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Wed, 07 Jan 2026
Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences - simplywall.st
Fri, 02 Jan 2026
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock - Investing.com
Mon, 29 Dec 2025
Biotech locks insiders out of selling stock for six years to back cancer trial - Stock Titan
Mon, 29 Dec 2025
Greenwich LifeSciences, Inc. Announces Extension of Lock-Up Period for Shares to September 30, 2026 - Quiver Quantitative
Fri, 26 Dec 2025
What's Going On With Greenwich LifeSciences Friday? - Greenwich LifeSciences (NASDAQ:GLSI) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 50.6 (%) |
| Held by Institutions | 9.5 (%) |
| Shares Short | 1,620 (K) |
| Shares Short P.Month | 1,580 (K) |
| EPS | -1.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -254.2 % |
| Return on Equity (ttm) | -543.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -15.35 |
| PEG Ratio | 0 |
| Price to Book value | 140.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -36.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|